Thompson Siegel & Walmsley LLC Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Thompson Siegel & Walmsley LLC boosted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 30.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 721,530 shares of the specialty pharmaceutical company's stock after purchasing an additional 168,957 shares during the quarter. Jazz Pharmaceuticals comprises approximately 1.2% of Thompson Siegel & Walmsley LLC's investment portfolio, making the stock its 19th largest holding. Thompson Siegel & Walmsley LLC owned about 1.14% of Jazz Pharmaceuticals worth $77,009,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Envestnet Asset Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 1.0% in the 2nd quarter. Envestnet Asset Management Inc. now owns 64,096 shares of the specialty pharmaceutical company's stock worth $6,841,000 after acquiring an additional 619 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals by 19.3% during the second quarter. Oppenheimer Asset Management Inc. now owns 7,846 shares of the specialty pharmaceutical company's stock worth $837,000 after purchasing an additional 1,272 shares during the last quarter. Johnson Investment Counsel Inc. grew its position in Jazz Pharmaceuticals by 23.1% in the 2nd quarter. Johnson Investment Counsel Inc. now owns 20,730 shares of the specialty pharmaceutical company's stock worth $2,213,000 after purchasing an additional 3,890 shares in the last quarter. Headlands Technologies LLC lifted its position in shares of Jazz Pharmaceuticals by 96.3% during the 2nd quarter. Headlands Technologies LLC now owns 9,607 shares of the specialty pharmaceutical company's stock worth $1,025,000 after buying an additional 4,714 shares in the last quarter. Finally, Royal London Asset Management Ltd. lifted its position in shares of Jazz Pharmaceuticals by 5.3% during the 2nd quarter. Royal London Asset Management Ltd. now owns 23,978 shares of the specialty pharmaceutical company's stock worth $2,559,000 after buying an additional 1,215 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Up 2.2 %

NASDAQ JAZZ traded up $2.34 during trading on Friday, hitting $108.79. The company had a trading volume of 654,261 shares, compared to its average volume of 688,344. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $137.38. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The company's fifty day moving average is $110.03 and its 200-day moving average is $111.40. The company has a market cap of $6.72 billion, a price-to-earnings ratio of 22.43, a price-to-earnings-growth ratio of 1.31 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1 billion. On average, sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

JAZZ has been the topic of several research analyst reports. Robert W. Baird lowered their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating on the stock in a research report on Thursday, August 1st. JPMorgan Chase & Co. upped their target price on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a report on Monday, August 19th. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, June 5th. They issued a "buy" rating and a $169.00 price target for the company. Morgan Stanley decreased their price target on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an "equal weight" rating on the stock in a report on Friday, July 12th. Finally, UBS Group dropped their price objective on Jazz Pharmaceuticals from $117.00 to $113.00 and set a "neutral" rating for the company in a research note on Tuesday, July 2nd. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $173.07.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.